Evidence map›Paper›PMID 41205132›Full record

ReviewInflammopharmacology2025

The promise of stem cell therapies for cellular recovery after stroke.

Heena Khan, Kavya Singh, Nirbhay Kumar Prabhakar, Amarjot Kaur Grewal, Thakur Gurjeet Singh

Abstract readReview
PubMed Publisher
In one paragraph

Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Heena KhanChitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India.
Kavya SinghChitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India.
Nirbhay Kumar PrabhakarChitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India.
Amarjot Kaur GrewalChitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India.
Thakur Gurjeet SinghChitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India. gurjeet.singh@chitkara.edu.in.ORCID http://orcid.org/0000-0003-2979-1590

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurological conditions are the consequence of impairment in the neuronal and glial cells. These neuronal disorders remain a significant concern for nations with industrialized economies. Even though our comprehension of the pathophysiology of strokes has grown over the past several years, greater understanding and additional education remain crucial for advancement in the field of stroke recovery. Present treatments are not optimal for each individual and cannot substantially improve the state of the disease. In the interim, the majority of the recipients still have neurological abnormalities even after receiving efficient thrombolysis; therefore, as soon as stroke damage takes place, recuperative therapies that foster brain reconfiguration and recognition are essential. Present treatments are not optimal for each individual and cannot substantially improve the state of the disease. Since the initial clinical trials were conducted more than 15 years ago, adult stem cells have been used for stem cell treatment in stroke patients. Although stem cells have shown potential in exploratory research and early therapeutic pilot studies, the use of cellular therapy to treat ischemic stroke is still in its infancy. Among the factors considered for cellular therapy for ischemic stroke are the types of stem cells, the mechanism of stem cell therapy, when and how to infuse stem cells, and the therapeutic applications of stem cell-based therapy for treating stroke.

Indexed as

Stem Cell TransplantationStrokeAnimalsCell- and Tissue-Based TherapyHumansRecovery of FunctionInflammationIschemiaOxidative damageStem cell therapyStroke

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.